Patients with cancer‐associated thrombosis (CAT) carry a higher risk of recurrence,
bleeding and mortality as compared with non‐cancer patients. The specific profiles of cancer …

Many cancer patients reportedly have a hypercoagulable state, with recurrent thrombosis
due to the impact of cancer cells and chemotherapy on the coagulation cascade. Studies …

Objectives. Venous thromboembolism (VTE) occurs more frequently in cancer patients than
in non-cancer patients and outcomes are poor in patients with both cancer and thrombosis …

Venous thromboembolism is a major complication in cancer patients. The basis for the
strong association between cancer and thrombosis remains incompletely understood, and …

Cancer is a known hypercoagulable state that leads to an increased risk of venous
thromboembolism (VTE). Low molecular weight heparin remains the preferred anticoagulant …

Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with
cancer and acute venous thromboembolism (VTE), but studies have reported inconsistent …

Background Current guidelines recommend several direct oral anticoagulant agents
(DOACs) equally for managing cancer-associated venous thromboembolism (VTE) …

Patients with active cancer are at high risk of recurrent venous thromboembolism (VTE).
Usual treatment includes low molecular weight heparin (LMWH), while vitamin K antagonists …

The association between venous thromboembolism (VTE) and cancer has been recognized
for more than 100 years. Numerous studies have been performed to investigate strategies to …

Therapeutic options for the management of venous thromboembolism have expanded with
the introduction of novel oral anticoagulants (NOACs). These agents offer significant …